All In Biotech

Drug Trial Radar · NCT06824194

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2 Arm Study to Investigate the Safety of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,360 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,360

Actual

Start

Feb 18, 2025

Primary completion

Oct 22, 2027

Study completion Oct 22, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.

Conditions

  • Pneumococcal Immunization

Interventions

  • PCV21 vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • Prevnar 20 vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • M-M-R II vaccineBiological

    Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular

  • RotarixBiological

    Pharmaceutical form:Solution-Route of administration:Oral

  • RotaTeqBiological

    Pharmaceutical form:Solution-Route of administration:Oral

  • Vaxelis vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • VarivaxBiological

    Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular

  • PriorixBiological

    Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous

  • VAQTABiological

    Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular

  • HavrixBiological

    Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of any immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
  2. Presence of solicited injection site and systemic reactions through 7 days after each vaccine injectionTime frame: Through 7 days after each vaccine injection
  3. Presence of unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs through 30 days after each vaccine injectionTime frame: Through 30 days after each vaccine injection
  4. Presence of serious adverse events (SAEs) throughout the study (through 6 months post- last vaccine injection)Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months
  5. Presence adverse events of special interest (AESIs) throughout the study (through 6 months post- last vaccine injection)Time frame: Throughout the study (through 6 months post-last vaccine injection), approximately 19 months

Locations

132 sites in 6 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400013

    Birmingham, Alabama

  • University of Alabama at Birmingham- Site Number : 8400130

    Birmingham, Alabama

  • Lakeview Clinical Research- Site Number : 8400054

    Guntersville, Alabama

  • Midway Medical Clinic- Site Number : 8400091

    Oneonta, Alabama

  • Noble Clinical Research- Site Number : 8400121

    Tucson, Arizona

  • The Children's Clinic- Site Number : 8400079

    Jonesboro, Arkansas

  • Helios CR, Inc. - Little Rock- Site Number : 8400090

    Sherwood, Arkansas

  • Helping Hands Healthcare Group - Fullerton- Site Number : 8400063

    Fullerton, California

  • Advanced Investigative Medicine- Site Number : 8400055

    Hawthorne, California

  • Century Research Institute- Site Number : 8400118

    Huntington Park, California

  • Matrix Clinical Research - Huntington Park- Site Number : 8400117

    Huntington Park, California

  • Matrix Clinical Research - Los Angeles- Site Number : 8400026

    Los Angeles, California

  • Matrix Clinical Research - Los Angeles- Site Number : 8400123

    Los Angeles, California

  • Alliance Research Institute - Lynwood- Site Number : 8400099

    Lynwood, California

  • Madera Family Medical Group- Site Number : 8400011

    Madera, California

  • FOMAT-Golden Valley Health Centers- Site Number : 8400084

    Merced, California

  • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400072

    Palo Alto, California

  • Center for Clinical Trials - Paramount- Site Number : 8400100

    Paramount, California

  • Integrated Clinical Research LLC- Site Number : 8400027

    Sherman Oaks, California

  • Emanate Health - Queen of the Valley Hospital- Site Number : 8400105

    West Covina, California

  • All In One Clinic- Site Number : 8400127

    Whittier, California

  • Amicis Research Center-Winnetka- Site Number : 8400128

    Winnetka, California

  • Emerson Clinical Research Institute - Washington - Connecticut Avenue- Site Number : 8400102

    Washington D.C., District of Columbia

  • D&H Doral Research Center- Site Number : 8400095

    Doral, Florida

  • Dolphin Medical Research, LLC- Site Number : 8400120

    Doral, Florida

  • Nextlevel Research Center- Site Number : 8400065

    Doral, Florida

  • CuraCare- Site Number : 8400125

    Kendall, Florida

  • PAS RESEARCH-Lutz- Site Number : 8400103

    Lutz, Florida

  • Abba Medical Research- Site Number : 8400064

    Miami, Florida

  • D&H National Research Center- Site Number : 8400085

    North Miami, Florida

  • Alfa Medical Research LLC- Site Number : 8400111

    Pembroke Pines, Florida

  • PAS Research - Tampa- Site Number : 8400113

    Tampa, Florida

  • Morehouse School of Medicine - Atlanta- Site Number : 8400093

    Atlanta, Georgia

  • CenExel - iResearch - Savannah- Site Number : 8400057

    Savannah, Georgia

  • Bingham Memorial Hospital - Blackfoot- Site Number : 8400114

    Blackfoot, Idaho

  • Elite Clinical Trials - Blackfoot- Site Number : 8400017

    Blackfoot, Idaho

  • Clinical Research Prime- Site Number : 8400022

    Idaho Falls, Idaho

  • Eagle Clinical Research- Site Number : 8400087

    Chicago, Illinois

  • University of Chicago Medical Center- Site Number : 8400062

    Chicago, Illinois

  • MidValley Research - Moline- Site Number : 8400096

    Moline, Illinois

Showing 40 of 132 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.